An experimental new treatment slows down the spread of metastatic prostate cancer, postponing the use of hormone treatment by at least 25 months, according to an international study headed by Nijmegen ... FDA approved niraparib, abiraterone acetate, and prednisone for BRCA2-mutated metastatic castration-sensitive prostate cancer, showing significant rPFS improvement in the AMPLITUDE trial. The ...
EurekAlert!: New Alliance trial aims to improve outcomes in metastatic prostate cancer Sept. 18, 2025 -- About 1 in 8 men will face a prostate cancer diagnosis. Early-stage prostate cancer often has no symptoms—so how should men approach screening and advocacy? What disparities do Black ...
metastatic prostate cancer life expectancy, Medical Xpress on MSN: Innovative targeted therapy halts prostate cancer spread to the bone Medical Xpress on MSN: PSMA therapy delays hormone therapy in prostate cancer, clinical trial finds Where previous research showed that PSMA therapy for prostate cancer can prolong the lives of patients who have exhausted all other treatment options, a new study now demonstrates that the therapy is ... Medscape: Are Transdermal Oestradiol Patches a Viable Alternative to LHRH Agonists for Locally Advanced Prostate Cancer?
